Reports

Drug name	NICE TAs	Comments
Nivolumab (Opdivo®)	TA384 - Nivolumab for treating advanced (unresectable or metastatic) melanoma TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma TA417 - Nivolumab for previously treated advanced renal cell carcinoma TA462 - Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma TA655 - Nivolumab for advanced squamous non-small cell lung cancer after chemotherapy TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA707 - Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma TA857 - Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer NICE TA 1065 Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Nonacog beta pego (Refixia®)		NHSE Commissioned
Normal Immunoglobulin Infusion
Normal Immunoglobulin Infusion FLEBOGAMMA
Normal Immunoglobulin Infusion GAMMAPLEX
Normal Immunoglobulin Infusion VIGAM
Nusinersen	TA588 - Nusinersen for treating spinal muscular atrophy
Nystatin pessaries (unlicensed)
Obeticholic acid (Ocaliva®)	TA443 - Obeticholic acid for treating primary biliary cholangitis	Off label use. Consultant initiation only (gastro use). Hospital only - in line with NICE TA443.
Obinutuzumab (Gazyvaro®)	TA343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia TA513 - Obinutuzumab for untreated advanced follicular lymphoma TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	For hospital use only Off label use - for thrombotic thrombocytopenic purpura (TTP)

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports